George Elston Eye Point Pharmaceuticals, Inc. (EYPT) insider trading activity

George Elston is Chief Financial Officer of EyePoint Pharmaceuticals, Inc.. Currently has a direct ownership of 91,852 shares of EYPT, which is worth approximately $1.09 Million. The most recent transaction as insider was on Jan 06, 2026, when has been sold 4,487 shares (Common Stock) at a price of $16.86 per share, resulting in proceeds of $75,650. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 91.9K

47.88% 3M change

33.96% 12M change

Total Value Held $1.09 Million

George Elston Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 06 2026	SELL Payment of exercise price or tax liability	$75,650 $16.86 p/Share	4,487 Reduced 4.66%	91,852 Common Stock
Jan 06 2026	BUY Exercise of conversion of derivative security	-	15,285 Added 13.69%	96,339 Common Stock
Jan 05 2026	SELL Payment of exercise price or tax liability	$76,744 $17.43 p/Share	4,403 Reduced 5.15%	81,054 Common Stock
Jan 05 2026	BUY Exercise of conversion of derivative security	-	15,000 Added 14.93%	85,457 Common Stock
Jan 03 2026	SELL Payment of exercise price or tax liability	$110,543 $17.48 p/Share	6,324 Reduced 8.24%	70,457 Common Stock
Jan 03 2026	BUY Exercise of conversion of derivative security	-	19,667 Added 20.39%	76,781 Common Stock
Dec 19 2025	SELL Bona fide gift	-	5,000 Reduced 8.05%	57,114 Common Stock

Sep 19 2025	SELL Bona fide gift	-	20,000 Reduced 24.36%	62,114 Common Stock
May 25 2025	SELL Payment of exercise price or tax liability	$12,507 $5.68 p/Share	2,202 Reduced 2.65%	80,848 Common Stock
May 25 2025	BUY Exercise of conversion of derivative security	-	7,500 Added 8.28%	83,050 Common Stock
Feb 09 2025	BUY Exercise of conversion of derivative security	-	5,834 Added 7.17%	75,550 Common Stock
Jan 06 2025	SELL Payment of exercise price or tax liability	$41,733 $8.68 p/Share	4,808 Reduced 6.55%	68,566 Common Stock
Jan 06 2025	BUY Exercise of conversion of derivative security	-	15,285 Added 17.24%	73,374 Common Stock
Jan 05 2025	SELL Payment of exercise price or tax liability	$43,505 $8.26 p/Share	5,267 Reduced 8.31%	58,089 Common Stock
Jan 05 2025	BUY Exercise of conversion of derivative security	-	15,000 Added 19.14%	63,356 Common Stock
May 25 2024	SELL Payment of exercise price or tax liability	$40,477 $11.16 p/Share	3,627 Reduced 7.1%	47,480 Common Stock
May 25 2024	BUY Exercise of conversion of derivative security	-	7,500 Added 12.8%	51,107 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$91,929 $28.8 p/Share	3,192 Reduced 6.82%	43,607 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	-	10,800 Added 18.75%	46,799 Common Stock
Jan 06 2024	SELL Payment of exercise price or tax liability	$100,184 $20.4 p/Share	4,911 Reduced 12.21%	35,308 Common Stock
Jan 06 2024	BUY Exercise of conversion of derivative security	-	15,285 Added 27.54%	40,219 Common Stock
Feb 09 2023	BUY Exercise of conversion of derivative security	-	10,800 Added 31.84%	23,116 Common Stock
Feb 09 2022	SELL Payment of exercise price or tax liability	$17,434 $10.13 p/Share	1,721 Reduced 15.2%	9,602 Common Stock
Feb 09 2022	BUY Exercise of conversion of derivative security	-	4,966 Added 30.49%	11,323 Common Stock

George Elston

Chief Financial Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EYPT shares.

Notify only if

Value

Insider Trading

Get notified when an Eye Point Pharmaceuticals, Inc. insider buys or sells EYPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to EyePoint Pharmaceuticals, Inc.

Track Activities on EYPT

Account